| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 04/21/2005 | US20050084482 As an antiinflammatory agent for gastrointestinal inflammation involved with inflammatory bowel disease or irritable bowel syndrome |
| 04/21/2005 | US20050084479 Especially lactic acid bacteria as drug delivery devices in combination with edible carriers; tissue targeted therapy |
| 04/21/2005 | US20050084463 Antiinflammatory, antiarthritic agents, analgesics for pain caused by diabetic assoicated conditions, pneumoconiosis, angina, menstruation or cancer |
| 04/21/2005 | CA2540977A1 Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| 04/21/2005 | CA2540147A1 Colon cleansing composition and method |
| 04/20/2005 | EP1524265A1 Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| 04/20/2005 | EP1523982A2 Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
| 04/20/2005 | EP1523577A2 Method for diagnosis of intestinal-type gastric tumors |
| 04/20/2005 | EP1523556A1 Methods of treating conditions associated with an edg-1 receptor |
| 04/20/2005 | EP1523486A2 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
| 04/20/2005 | EP1523480A2 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 04/20/2005 | EP1523473A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 04/20/2005 | EP1523470A1 Novel compounds as histone deacetylase inhibitors |
| 04/20/2005 | EP1523321A1 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 04/20/2005 | EP1523316A2 Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer |
| 04/20/2005 | EP1523311A1 Calcium lactate and whey permeate for lowering the triglyceride level |
| 04/20/2005 | EP1443934B1 Benzotriazepines as gastrin and cholecystokinin receptor ligands |
| 04/20/2005 | EP1373249B1 Imidazolidine derivatives, their preparation, and their use as antiinflamatory agent |
| 04/20/2005 | EP1349843B1 Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| 04/20/2005 | EP1307425B1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 04/20/2005 | EP1252158B1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| 04/20/2005 | EP1240212B1 Crosslinked copolymers based on non-crosslinked polycarboxylic copolymers |
| 04/20/2005 | EP1144395B1 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 04/20/2005 | EP1143977B1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 04/20/2005 | EP1129077B1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 04/20/2005 | EP0775213B1 Adenovirus comprising a gene coding for glutathion peroxidase |
| 04/20/2005 | CN1608069A Selective androgen receptor modulators and methods for their identification, design and use |
| 04/20/2005 | CN1608068A Bridged bicyclic amino acid-derived [1, 4]benzodiazepine vasopressin receptor antagonists |
| 04/20/2005 | CN1608067A Pyrrolopyrimidines as phosphodiesterase vii inhibitors |
| 04/20/2005 | CN1608065A Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase and pharmaceutical compositions containing the compounds |
| 04/20/2005 | CN1608064A Novel compounds |
| 04/20/2005 | CN1608062A Salt forms of e-2-methoxy-n-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| 04/20/2005 | CN1608061A Therapeutic isoquinoline compounds |
| 04/20/2005 | CN1608059A Bipyridyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/20/2005 | CN1608055A Compounds for the treatment of metabolic disorders |
| 04/20/2005 | CN1608054A Therapeutic quinolone compounds with 5-HT-antagonistic properties |
| 04/20/2005 | CN1607960A Glycoprotein compositions |
| 04/20/2005 | CN1607959A Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
| 04/20/2005 | CN1607951A Quinoline derivatives as neuropeptide y antagonists |
| 04/20/2005 | CN1607209A Poly thymosin-alpha 1, its composition, its preparation method and application |
| 04/20/2005 | CN1607005A Soluble lymphotoxin- beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| 04/20/2005 | CN1607003A Auxiliary therapeutic agent for C type hepatitis |
| 04/20/2005 | CN1606990A Stomach and intestine strengthening medicine |
| 04/20/2005 | CN1606989A Soft capsule with peppermint oil as raw material medicine for treating gallbladder disease |
| 04/20/2005 | CN1197966C Modulators of TNF receptor associated factor (TRAF), their preparation and use |
| 04/20/2005 | CN1197877C AsLc-IFN fusion protein and its preparation |
| 04/20/2005 | CN1197861C Method for preparing solid optical pure neutral S- (-) - and (R) - (+) -Omeprazole |
| 04/20/2005 | CN1197849C 2, 3, 4, 5-tetrahydro-1H-[1, 4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
| 04/20/2005 | CN1197621C Medicinal compositions promoting bowel movement |
| 04/20/2005 | CN1197611C Medicine for treating choleithiasis and preparing method thereof |
| 04/20/2005 | CN1197595C Chinese medicine preparation for broad-spectrum inflammation relieving, disinfecting, erosion prevention and muscle growing |
| 04/20/2005 | CN1197593C Gelatin for treating colonitis and preparation process thereof |
| 04/20/2005 | CN1197584C Pourable alginate compositions |
| 04/20/2005 | CN1197562C Application of sodium ferulate in preparing medicine to prevent and cure heptofibrosis |
| 04/20/2005 | CN1197556C Tablet disintegrated in mouth rapidly for preventing and curing radiotherapeutic and chemotherapeutic vomit, and its preparing method |
| 04/19/2005 | US6881831 Treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units. |
| 04/19/2005 | US6881754 Adamantane derivatives |
| 04/19/2005 | US6881748 Drug targeting |
| 04/19/2005 | US6881741 Such as 3-(4-Chloro-2,5-dimethyl-benzenesulfonylamino)-5-(4-chloro-phenyl)-thiophene-2-carboxylic acid; for treatment of hepatitis |
| 04/19/2005 | US6881740 Pharmaceutical agents |
| 04/19/2005 | US6881739 Use of cortisol antagonists in the treatment of heart failure |
| 04/19/2005 | US6881735 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 04/19/2005 | US6881734 Pharmaceutical composition for the treatment of CNS and other disorders |
| 04/19/2005 | US6881730 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy |
| 04/19/2005 | CA2110497C Use of bacterial lipases for producing drugs for maldigestion therapy |
| 04/14/2005 | WO2005033254A1 Body fat burn spurring perfume composition |
| 04/14/2005 | WO2005033123A1 Stable vitamin b6 derivative |
| 04/14/2005 | WO2005033109A1 Triazinoindolamine compound |
| 04/14/2005 | WO2005032580A1 Methods and compositions for treating eosinophil mediated gastro-intestinal dysfunction or disease |
| 04/14/2005 | WO2005032579A1 Method of regenerating human tissue |
| 04/14/2005 | WO2005032576A1 Therapeutic agent for hepatitis c |
| 04/14/2005 | WO2005032571A2 Method for the production of a medicinal tincture from higher mushrooms, medicinal tincture and use thereof |
| 04/14/2005 | WO2005032542A1 Neutralizing agent for cavitating toxin |
| 04/14/2005 | WO2005032520A1 Buccal, polar and non-polar spray containing ondansetron |
| 04/14/2005 | WO2005032462A2 Glucocerebroside treatment of disease |
| 04/14/2005 | WO2004091597A3 Method of treating irritable bowel syndrome (ibs) |
| 04/14/2005 | WO2004014295A3 Tiacumicin production |
| 04/14/2005 | WO2003063573A3 Method for treating diseases with omega interferon |
| 04/14/2005 | WO2003051287A3 Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| 04/14/2005 | WO2003027228A3 Receptors and membrane-associated proteins |
| 04/14/2005 | US20050080257 Benzo'fisoindole derivatives with affinity to the ep4 receptor |
| 04/14/2005 | US20050080137 Laxative preparation |
| 04/14/2005 | US20050080136 Spray drying in the presence of trehalose, then granulating and drying; leucine, isoleucine, valine powders; oral meltability and solubility and a high masking effect of the taste |
| 04/14/2005 | US20050080129 Derivatives of andrimide and moiramide b having antibacterial properties |
| 04/14/2005 | US20050080120 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body |
| 04/14/2005 | US20050080119 Diaminopropionic acid derivatives |
| 04/14/2005 | US20050080117 Substituted benzoxazoles as estrogenic agents |
| 04/14/2005 | US20050080107 Inhibitor of phosphodiesterase enzyme, 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid monohydrate; treating inflammatory diseases, diabetics, allergic diseases, autoimmune diseases, ocular diseases, osteoporosis, Parkinson's disease, dementia; chemical intermediates |
| 04/14/2005 | US20050080104 Preparing 3-[(4S)-5-oxo-2-(trifluoromethyl)-1,4,5,6,7,8-hexahydroquinolin-4-yl]benzonitrile by reacting an ester of 4,4,4-trifluoro-3-oxobutanoate with 1,3-cyclohexanedione and 3-cyanobenzaldehyde, , dehydrating and de-esterifying the intermeidate |
| 04/14/2005 | US20050080096 Condensed heterocyclic compounds |
| 04/14/2005 | US20050080073 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators |
| 04/14/2005 | US20050080067 Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells |
| 04/14/2005 | US20050080064 Steroids as agonists for fxr |
| 04/14/2005 | US20050080050 Lipid analogs for treating viral infections |
| 04/14/2005 | US20050080046 In liquid solvent; parenterally administering; aldosterone receptors blockers; congestive heart failure, hypotensive agents, liver disorders |
| 04/14/2005 | US20050080026 Nucleic acid molecule of MAP kinase interacting kinase gene family or polypeptide encoded thereby or fragment or variant of nucleic acid molecule, polypeptide or antibody, aptamer or receptor recognizing a nucleic acid molecule of gene family or polypeptide encoded thereby; treating metabolic diseases |
| 04/14/2005 | US20050080010 Suppression of immune response via inhibition of cathepsin S |
| 04/14/2005 | US20050079996 Remedies for liver diseases, hyperlipemia and diabetes |
| 04/14/2005 | US20050079597 Antimicrobial composition |
| 04/14/2005 | US20050079581 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor |